Halozyme Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of products targeting the extracellular matrix for the drug delivery, oncology, and dermatology markets. The company's portfolio of products and product candidates is based on intellectual property covering the family of human enzymes known as hyaluronidases. The company's Enhanze Technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. Its products include Cumulase for use in in-vitro fertilization, and HYLENEX for use as an adjuvant to increase the absorption and dispersion of other injected drugs and fluids. The company also provides Chemophase, an investigative chemoadjuvant to enhance the transport of chemotherapeutic agents to tumor tissue. It has partnerships with Roche to apply Enhanze Technology to Roche's biological therapeutic compounds; and with Baxter to apply Enhanze Technology to Baxter's biological therapeutic compound, GAMMAGARD LIQUID 10%. The company was founded in 1998 and is based in San Diego, California.
$5.55 (06/27/08)
